Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
주식 순위 #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
주가
$0.94180721
시가총액
$22.26M
변동 (1일)
0.38%
변동 (1년)
-14.35%
국가
FR
거래 Valbiotis SA (ALVAL)

카테고리

Valbiotis SA (ALVAL)의 EPS
December 2025 기준 EPS TTM: $-0.57
Valbiotis SA의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.57입니다. 2023년 말에는 회사의 EPS가 $-0.65였으며, 이는 2022년의 EPS $-1.31와 감소입니다.
Valbiotis SA의 EPS 기록 (2015 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-0.57 -12.89%
2024 $-0.66 0.52%
2023 $-0.65 -50.16%
2022 $-1.31 21.14%
2021 $-1.08 73.93%
2020 $-0.62 -52.69%
2019 $-1.31 -13.46%
2018 $-1.52 37.41%
2017 $-1.10 517.05%
2016 $-0.18 -99.73%
2015 $-65.94 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$4.36 -858.10%
DK
$17.01 -3,058.78%
US
$42.53 -7,497.81%
US
$9.62 -1,773.47%
BE
$23.88 -4,253.77%
NL